Biopeak, a health-tech startup, has successfully secured $2.7 million in a follow-up funding round led by NKSquared, the investment arm of Zerodha cofounder Nikhil Kamath. This marks Kamath’s second investment in the company, having previously contributed $1.43 million to the health optimisation startup in August 2024. The funds will be directed towards expanding operations, which includes launching a new clinic and upgrading its diagnostics, proprietary artificial intelligence (AI) tools, research projects, and clinical programmes, as stated in a press release from Biopeak.
Highlights
Understanding Biopeak’s Mission
Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak employs AI-driven molecular diagnostics, imaging, and expert-led programmes to enhance healthspan. The startup is dedicated to longevity by offering a “family health office” model, delivering custom plans aimed at extending healthspan.
Innovative Health Solutions
The platform incorporates various advanced tools including organic acid profiling, microbiome mapping, whole-exome functional genomics, salivary cortisol rhythms, and imaging technologies such as MRI, CT, DXA, and ECHO. Biopeak’s in-house clinics focus on providing specialized care based on data-driven, actionable insights related to nutrition, sleep, and stress management.
Target Audience
Located in Bengaluru, Biopeak specifically targets high achievers, executives, and women, utilising programmes that integrate cutting-edge diagnostics, specialist teams, wearable data, and AI insights tailored to align with Indian biology and disease patterns. The operational model emphasizes early risk detection, longitudinal monitoring, and targeted interventions to bolster performance and resilience.
Recent Growth and Future Plans
Over the last year, Biopeak has expanded both its client base and clinical services in response to the increasing demand for structured longevity solutions. The startup opened a clinic in Bengaluru last year and plans to launch a second clinic in the upcoming month.
